NEWS
ROCHE UNVEILS A NEW CLASS OF NEXT-GENERATION SEQUENCING WITH ITS NOVEL SEQUENCING BY EXPANSION TECHNOLOGY
“ The science behind SBX technology represents a significant breakthrough that addresses the limitations of existing sequencing solutions ,” said Matt Sause , CEO of Roche Diagnostics . “ By integrating and enhancing the two technologies , Roche ’ s SBX has created a differentiated approach , offering unparalleled speed , efficiency and flexibility . The speed and accuracy of SBX has the potential to revolutionise the use of sequencing in research and healthcare .”
Roche has unveiled its proprietary , breakthrough sequencing by expansion ( SBX ) technology , establishing a new category of next-generation sequencing . SBX chemistry , combined with an innovative sensor module , offers ultra-rapid , high-throughput sequencing that is both flexible and scalable for a broad range of applications .
Next-generation sequencing provides detailed insights into genetics , genomics and cell biology . It has already improved our understanding of gene functions and interaction , and is critical to our ability to decode complex diseases such cancer , immune disorders and neurodegenerative conditions , where hundreds or even thousands of genes impact disease progression .
TEMPUS AND STEMLINE PARTNER TO IMPLEMENT AI PLATFORM FOR METASTATIC BREAST CANCER
Tempus and Stemline Therapeutics , a subsidiary of the Menarini Group , have announced a collaboration to implement Tempus Next , an AI-enabled care pathway intelligence platform , to support patients with metastatic breast cancer ( mBC ). Up to 50 % of patients with ER +/ HER2- mBC may develop ESR1 mutations due to prior exposure to endocrine therapy . Identifying these mutations through testing can help clinicians make more informed treatment decisions .
Tempus ’ Next platform will analyse clinical data from mBC patients and notify clinicians when ESR1 testing is missing during disease progression . The American Society of Clinical Oncology ( ASCO ) recommends ESR1 mutation testing at each stage of mBC progression . Since ESR1 mutations are subclonal and heterogeneous , tissue biopsy may not detect them , making liquid biopsy a preferred method for its higher sensitivity .
The Next platform helps clinicians by providing timely notifications within their workflow when ESR1 testing is needed , ensuring this critical step is integrated into the patient ’ s care plan . This collaboration aims to enhance treatment decisions , optimising care and outcomes for patients with mBC .
www . intelligenthealth . tech 9